Apricus Biosciences (NASDAQ: APRI) and Innocoll (NASDAQ:INNL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.
Institutional & Insider Ownership
24.0% of Apricus Biosciences shares are held by institutional investors. Comparatively, 34.2% of Innocoll shares are held by institutional investors. 3.6% of Apricus Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Apricus Biosciences and Innocoll, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Apricus Biosciences currently has a consensus target price of $5.00, suggesting a potential upside of 112.77%. Innocoll has a consensus target price of $3.00, suggesting a potential upside of 27.66%. Given Apricus Biosciences’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Apricus Biosciences is more favorable than Innocoll.
Valuation & Earnings
This table compares Apricus Biosciences and Innocoll’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Apricus Biosciences||$5.76 million||6.21||-$7.43 million||$0.58||4.05|
Innocoll has lower revenue, but higher earnings than Apricus Biosciences. Innocoll is trading at a lower price-to-earnings ratio than Apricus Biosciences, indicating that it is currently the more affordable of the two stocks.
This table compares Apricus Biosciences and Innocoll’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Apricus Biosciences beats Innocoll on 9 of the 11 factors compared between the two stocks.
Apricus Biosciences Company Profile
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.
Innocoll Company Profile
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.